Research Topics
| D S BaldwinSummaryAffiliation: University of Southampton Country: UK Publications
| Collaborators
|
Detail Information
Publications
Evidence-based pharmacotherapy of Generalized Anxiety DisorderDavid S Baldwin
Clinical Neurosciences Division, Faculty of Medicine, Health and Life Sciences, University of Southampton, UK
Int J Neuropsychopharmacol 8:293-302. 2005..The management of patients who do not respond to first-line treatment is uncertain, but some patients may benefit from certain tricyclic antidepressants, buspirone, or pregabalin...- Discontinuation symptoms in depression and anxiety disordersDavid S Baldwin
Clinical Neurosciences Division, School of Medicine, University of Southampton, UK
Int J Neuropsychopharmacol 10:73-84. 2007..Thus, discontinuation profiles differ between antidepressants of the same class and are broadly similar in different disorders. No evidence was seen for a higher discontinuation burden with longer treatment... - Escitalopram and paroxetine in the treatment of generalised anxiety disorder: randomised, placebo-controlled, double-blind studyDavid S Baldwin
Neuroscience Division, School of Medicine, University of Southampton, Royal South Hants Hospital, Graham Road, Southampton SO14 0YG, UK
Br J Psychiatry 189:264-72. 2006..It is uncertain whether higher doses of selective serotonin reuptake inhibitors have greater efficacy in generalised anxiety disorder... - An international survey of reported prescribing practice in the treatment of patients with generalised anxiety disorderDavid S Baldwin
University of Southampton Faculty of Medicine, Southampton, UK
World J Biol Psychiatry 13:510-6. 2012..To gain insight into the experience and practice of psychiatrists in the pharmacological management of patients with generalized anxiety disorder (GAD)... - A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD)David S Baldwin
Clinical and Experimental Sciences Academic Unit, Faculty of Medicine, University of Southampton, United Kingdom
Eur Neuropsychopharmacol 22:482-91. 2012..Findings on secondary outcome measures, using MMRM instead of LOCF, were supportive of likely efficacy for Lu AA21004 5mg and 10mg and duloxetine. Lu AA21004 (2.5, 5 and 10 mg) was well tolerated... - Lu AA21004, a multimodal psychotropic agent, in the prevention of relapse in adult patients with generalized anxiety disorderDavid S Baldwin
Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK
Int Clin Psychopharmacol 27:197-207. 2012..In this study, Lu AA21004 5 or 10 mg/day was efficacious in preventing relapse and was well tolerated in the maintenance treatment of GAD... - Does early improvement predict endpoint response in patients with generalized anxiety disorder (GAD) treated with pregabalin or venlafaxine XR?David S Baldwin
University of Southampton, UK
Eur Neuropsychopharmacol 22:137-42. 2012.... - The pharmacologic treatment of patients with generalized anxiety disorder: where are we now and where are we going?David S Baldwin
Department of Psychiatry, Royal South Hants Hospital, Southampton, UK
CNS Spectr 14:5-12. 2009..Future guidelines will be influenced by emerging data with both established and novel drug treatments, and through better identification of patient groups that are likely to respond preferentially to particular interventions... - A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorderDavid S Baldwin
Clinical Neuroscience Division, University of Southampton, Royal South Hants Hospital, Southampton, UK
Int Clin Psychopharmacol 21:159-69. 2006..During taper and cessation of treatment, patients in the paroxetine group demonstrated significantly more discontinuation symptoms relative to escitalopram based on the Discontinuation Emergent Signs and Symptoms scores... - Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for PsychopharmacologyDavid S Baldwin
Division of Clinical Neurosciences, University of Southampton, Southampton, UK
J Psychopharmacol 19:567-96. 2005..The guidelines cover the diagnosis of anxiety disorders and key steps in clinical management, including acute treatment, relapse prevention and approaches for patients who do not respond to first-line treatments... - Resolution of sexual dysfunction during double-blind treatment of major depression with reboxetine or paroxetineDavid Baldwin
Clinical Neuroscience Division, School of Medicine, University of Southampton, Southhampton, UK
J Psychopharmacol 20:91-6. 2006..Sexual function and satisfaction in depressed patients improves during double-blind acute treatment with reboxetine or paroxetine, but this improvement is greater and more rapid with reboxetine... - Selective serotonin re-uptake inhibitor treatment-emergent sexual dysfunction: randomized double-blind placebo-controlled parallel-group fixed-dose study of a potential adjuvant compound, VML-670David Baldwin
Clinical Neuroscience Division, University of Southampton, Southampton, UK
J Psychopharmacol 22:55-63. 2008..3%). Double-blind treatment with VML-670 offered no significant advantage over placebo on the primary outcome measure in the overall sample. Further studies may be warranted in larger groups of male patients with sexual dysfunction... - Escitalopram therapy for major depression and anxiety disordersDavid S Baldwin
Clinical Neuroscience Division, University Department of Mental Health, Royal South Hants Hospital, Southampton, England
Ann Pharmacother 41:1583-92. 2007..Randomized controlled clinical trials have demonstrated that escitalopram is efficacious in a range of mood and anxiety disorders, but the individual trials are insufficiently large to allow a full exploration of its tolerability... - Room for improvement in the pharmacological treatment of anxiety disordersD S Baldwin
Department of Mental Health, Royal South Hants Hospital, Brintons Terrace, Southampton SO14 0YG, UK
Curr Pharm Des 14:3482-91. 2008.... - How long should a trial of escitalopram treatment be in patients with major depressive disorder, generalised anxiety disorder or social anxiety disorder? An exploration of the randomised controlled trial databaseDavid S Baldwin
Clinical Neuroscience Division, School of Medicine, University of Southampton, Southampton, UK
Hum Psychopharmacol 24:269-75. 2009.... - Manifesto for a European anxiety disorders research networkDavid S Baldwin
Clinical Neuroscience Division, University of Southampton School of Medicine, Southampton, UK
Eur Neuropsychopharmacol 20:426-32. 2010..The Anxiety Disorders Research Network (ADRN) has been adopted within the ECNP-NI: this consensus statement summarises its overall aims and objectives... - Evidence-based pharmacological treatment of generalized anxiety disorderDavid S Baldwin
Clinical Neuroscience Division, School of Medicine, University of Southampton, UK
Int J Neuropsychopharmacol 14:697-710. 2011..There have been few investigations of the further management of patients who have not responded to first-line treatment, but switching to another evidence-based treatment, or augmentation approaches may be beneficial... - Pharmacological treatment of generalized anxiety disorderDavid S Baldwin
Clinical Neuroscience Division, School of Medicine, University of Southampton, Southampton, UK
Curr Top Behav Neurosci 2:453-67. 2010.... - Escitalopram in the treatment of generalized anxiety disorderDavid S Baldwin
Division of Clinical Neurosciences, University Department of Mental Health, RSH Hospital, Graham Road, Southampton, SO14 0YG, UK
Expert Rev Neurother 5:443-9. 2005..In summary, escitalopram is effective and well tolerated in both the short- and long-term treatment of generalized anxiety disorder, and has advantages over benzodiazepines and the selective serotonin reuptake inhibitor paroxetine... - Sexual dysfunction associated with antidepressant drugsDavid S Baldwin
University Department of Mental Health, RSH Hospital, RSH Hospital, Graham Road, Southampton, SO14 0YG, UK
Expert Opin Drug Saf 3:457-70. 2004.... - Placebo-controlled studies in depression: necessary, ethical and feasibleDavid Baldwin
University Department of Mental Health, Royal South Hants Hospital, Brintons Terrace, Southampton, UK
Eur Arch Psychiatry Clin Neurosci 253:22-8. 2003..Placebo-controlled studies of new antidepressants are justified, both scientifically and ethically; restrictions on placebo-controlled investigations will hinder the arrival of more efficacious and better tolerated antidepressants... - Can we distinguish anxiety from depression?David S Baldwin
Department of Psychiatry, University of Southampton, Hampshire, United Kingdom
Psychopharmacol Bull 36:158-65. 2002..There is still uncertainty regarding the neurobiological cause, but it is probably linked to dysregulation in the serotonergic and noradrenergic systems... - A randomized, double-blind controlled comparison of nefazodone and paroxetine in the treatment of depression: safety, tolerability and efficacy in continuation phase treatmentD S Baldwin
Community Clinical Sciences Research Division, Faculty of Medicine, Health and Biological Sciences, University of Southampton, UK
J Psychopharmacol 15:161-5. 2001..Headache and somnolence were the most common reported adverse events in both treatment groups. Both nefazodone and paroxetine maintain their efficacy in continuation treatment, and both are generally well tolerated... - Short-term treatment with hypnotic drugs for insomnia: going beyond the evidenceDavid Baldwin
Clinical Neuroscience Division, University of Southampton, Southampton, UK
J Psychopharmacol 19:134-5. 2005 - Clinical experience with paroxetine in social anxiety disorderD S Baldwin
Department of Mental Health, University of Southampton, UK
Int Clin Psychopharmacol 15:S19-24. 2000..Taken together, these studies confirm that paroxetine is an effective and well tolerated treatment for patients with social anxiety disorder... - Social anxiety symptoms across diagnoses among outpatients attending a tertiary care mood and anxiety disorders serviceH J Graystone
Clinical Neuroscience Division, School of Medicine, University of Southampton, University Department of Mental Health, RSH Hospital, Brintons Terrace, Southampton, SO14 0YG UK
J Affect Disord 114:305-9. 2009..Social phobia is a common, persistent and disabling anxiety disorder in which co-existing depressive symptoms are common. However the prevalence of social anxiety symptoms in patients with other mood and anxiety disorders is uncertain... - The Wessex Recent In-Patient Suicide Study, 2. Case-control study of 59 in-patient suicidesE A King
Mental Health Group, Department of Psychiatry, The University of Southampton, Southampton, UK
Br J Psychiatry 178:537-42. 2001..Psychiatric patients have an elevated risk of suicide while in hospital... - Veterinary surgeons and suicide: a structured review of possible influences on increased riskD J Bartram
Division of Clinical Neurosciences, School of Medicine, University of Southampton, RSH Hospital, Brintons Terrace, Southampton SO14 0YG
Vet Rec 166:388-97. 2010.... - A cross-sectional study of mental health and well-being and their associations in the UK veterinary professionDavid J Bartram
Division of Clinical Neurosciences, School of Medicine, RSH Hospital, University of Southampton, Brintons Terrace, Southampton SO14 0YG, UK
Soc Psychiatry Psychiatr Epidemiol 44:1075-85. 2009..We aimed to assess the contribution of mental health and well-being to the elevated risk, through a postal questionnaire survey of a large stratified random sample of veterinary surgeons practising within the UK... - Depression and sexual dysfunctionD S Baldwin
Community Clinical Sciences Research Division, Faculty of Medicine, Health and Biological Sciences, University of Southampton, UK
Br Med Bull 57:81-99. 2001..There is a need for further studies of the effects of antidepressants on sexual function... - Elderly suicide rates in Asian and English-speaking countriesC Pritchard
Department of Mental Health, Faculty of Medicine, Health and Biological Sciences, University of Southampton, Southampton, UK
Acta Psychiatr Scand 105:271-5. 2002..Asian culture venerates elderly people. It was hypothesized that elderly suicides would be proportionately lower in Asian societies than in English-speaking countries (ESC)... - Quantifying subjective assessment of sleep and life-quality in antidepressant-treated depressed patientsAndrew G Mayers
University Department of Psychiatry, University of Southampton, UK
Hum Psychopharmacol 18:21-7. 2003..These results confirm the extent of subjectively reported sleep disruption in depression and demonstrate the merit of combining the amended PghSD and QOLI to quantify sleep perceptions... - Impaired identification of fearful faces in Generalised Social PhobiaMatthew Garner
Division of Clinical Neuroscience, School of Medicine, University of Southampton, SO17 1BJ, United
J Affect Disord 115:460-5. 2009..The present study is novel in using a signal detection approach to clarify whether Generalised Social Phobia (GSP) is associated with biased identification of emotionally ambiguous facial expressions... 
Attentional biases in clinical populations with alcohol use disorders: is co-morbidity ignored?Julia M A Sinclair
Mental Health Group, Division of Clinical Neurosciences, School of Medicine, University of Southampton, UK
Hum Psychopharmacol 25:515-24. 2010..To identify how psychiatric co-morbidity was identified and assessed, in studies of attentional bias in clinical samples of patients with alcohol use disorders (AUDs)...- Research in anxiety disorders: from the bench to the bedsideMatthew Garner
School of Psychology and Division of Clinical Neurosciences, School of Medicine, University of Southampton, UK
Eur Neuropsychopharmacol 19:381-90. 2009..Clinical and neurobiological predictors of active treatment and placebo response are considered... - Escitalopram: efficacy and tolerability in the treatment of depressionDavid S Baldwin
Community Clinical Sciences, Research Division, Faculty of Medicine, Health and Biological Sciences, University Department of Mental Health, University of Southampton, Royal South Hants Hospital, Southampton SO14 0YG
Hosp Med 63:668-71. 2002..This review describes the properties of escitalopram, summarizes the results of randomized controlled trials, and suggests that escitalopram has advantages over citalopram in the treatment of depression... - Evidence-based guidelines for anxiety disorders: can they improve clinical outcomes?David S Baldwin
Department of Psychiatry, Royal South Hants Hospital, Southampton, United Kingdom
CNS Spectr 11:34-9. 2006.... - Assessing subjective sleep reports in the first-degree relatives of antidepressant-treated depressed outpatientsAndrew G Mayers
University Department of Psychiatry, University of Southampton, UK
Hum Psychopharmacol 18:207-14. 2003..Reports of poor sleep may be associated with reports of poor mood in depression, but in non-depressed individuals the association may be with a feeling of weariness... - Antidepressants and their effect on sleepAndrew G Mayers
Perinatal Mental Health, University of Southampton, UK
Hum Psychopharmacol 20:533-59. 2005.... - Effect of short-term SSRI treatment on cognitive bias in generalised anxiety disorderKarin Mogg
Centre for the Study of Emotion and Motivation, School of Psychology, University of Southampton, Highfield, Southampton, SO171BJ, UK
Psychopharmacology (Berl) 176:466-70. 2004..Cognitive theories of anxiety, which provide the basis of cognitive-behaviour therapy, propose that such processing biases play an important role in causing and maintaining anxiety... - The Wessex Recent In-Patient Suicide Study, 1. Case-control study of 234 recently discharged psychiatric patient suicidesE A King
Mental Health Group, Department of Psychiatry, The University of Southampton, Southampton, UK
Br J Psychiatry 178:531-6. 2001..Psychiatric patients have a higher suicide risk following hospital discharge... - Interventions with potential to improve the mental health and wellbeing of UK veterinary surgeonsD J Bartram
University of Southampton, Royal South Hants Hospital, Brintons Terrace, Southampton SO14 0YG
Vet Rec 166:518-23. 2010..This paper proposes a portfolio of evidence-based interventions, for both organisations and individuals, which have the potential to improve mental health and wellbeing in the veterinary profession... - Symptoms of fatigue and sleepiness in major depressive disorderDavid S Baldwin
Faculty of Medicine, Health, and Life Sciences, University of Southampton, UK
J Clin Psychiatry 67:9-15. 2006.... - Agomelatine in the treatment of mood and anxiety disordersDavid S Baldwin
Clinical Neuroscience Division, School of Medicine, University of Southampton, Southhampton
Br J Hosp Med (Lond) 71:153-6. 2010..What is its potential role in clinical practice?.. - Suicide in schizophrenia: a retrospective case-control study of 51 suicidesJulia M A Sinclair
Department of Psychiatry, Warneford Hospital, Oxford OX3 7JX, UK
Schizophr Bull 30:803-11. 2004..Suicide of individuals is difficult to predict in patients with schizophrenia. Young men appear particularly vulnerable at times of inpatient care. Depressive symptoms and previous suicide attempts are significant risk factors... - Recurrent brief depression--more investigations in clinical samples are now requiredDavid S Baldwin
Psychol Med 33:383-6. 2003 - Cost-effectiveness analysis of escitalopram compared with paroxetine in treatment of generalized anxiety disorder in the United KingdomTine Rikke Jørgensen
International Department of Health Economics and Epidemiology, H Lundbeck A S, Copenhagen, Denmark
Ann Pharmacother 40:1752-8. 2006..Generalized anxiety disorder (GAD) is associated with substantial economic burden... - What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder?Borwin Bandelow
Department of Psychiatry and Psychotherapy, University of Gottingen, Gottingen, Germany
J Clin Psychiatry 67:1428-34. 2006..We also sought to compare the standardized effect sizes of escitalopram for these 4 psychiatric disorders... - Which factors predict placebo response in anxiety disorders and major depression? An analysis of placebo-controlled studies of escitalopramDan J Stein
Department of Psychiatry, University of Cape Town, South Africa
J Clin Psychiatry 67:1741-6. 2006.... - Estimating the prevalence and impact of antidepressant-induced sexual dysfunction in 2 European countries: a cross-sectional patient surveyValerie S L Williams
RTI Health Solutions, Research Triangle Park, NC 27709 2194, USA
J Clin Psychiatry 67:204-10. 2006..The aim of this study was to estimate the prevalence and impact of sexual dysfunction during antidepressant treatment in 2 European countries... - Effects of venlafaxine extended release on resilience in posttraumatic stress disorder: an item analysis of the Connor-Davidson Resilience ScaleJonathan Davidson
Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Trent Drive, 4th Floor, Room 4082B, Durham, NC 27710, USA
Int Clin Psychopharmacol 23:299-303. 2008..The findings suggest that assessment of treatment response might be enhanced by routine evaluation of resilience... - The overlap of obsessive-compulsive disorder and social phobia and its treatmentDavid S Baldwin
Strategic Center of Excellence of Psychiatry, Department of Psychiatry, Mount Sinai School of Medicine, New York, NY, USA
CNS Spectr 13:47-53. 2008..Psychologic intervention should draw on the range of cognitive and behavioral approaches required for optimal outcomes in OCD and social phobia, as discrete conditions... - Suicide in depressive disorders: a retrospective case-control study of 127 suicidesJulia M A Sinclair
Centre for Suicide Research, UK
J Affect Disord 87:107-13. 2005..Depressive disorders are associated with a significant risk of suicide. Inpatient status and recent discharge from hospital have been identified as times of high risk of suicide within the course of illness... - Do SSRIs or antidepressants in general increase suicidality? WPA Section on Pharmacopsychiatry: consensus statementHans Jurgen Moller
Department of Psychiatry, Ludwig Maximilians University Munchen, Nussbaumstrasse 7, 80336 Munich, Germany
Eur Arch Psychiatry Clin Neurosci 258:3-23. 2008..It is the major problem facing efforts to identify the possible 'suicidal effects' of antidepressants... - Antidepressant medications and other treatments of depressive disorders: a CINP Task Force report based on a review of evidenceNorman Sartorius
Chairperson of CINP Task Force, 14 Chemin Colladon, Geneva, Switzerland
Int J Neuropsychopharmacol 10:S1-207. 2007 - Which antidepressants have demonstrated superior efficacy? A review of the evidenceStuart A Montgomery
Imperial College School of Medicine, University of London, UK
Int Clin Psychopharmacol 22:323-9. 2007..This review of published data found evidence that only a very few antidepressants are shown to be more effective than others... - Consensus statement and research needs: the role of dopamine and norepinephrine in depression and antidepressant treatmentDavid J Nutt
Psychopharmacology Unit, School of Medical Sciences, University of Bristol, Bristol, UK
J Clin Psychiatry 67:46-9. 2006..In addition, the faculty discussed the importance of patient psychoeducation and self-management as well as the ways in which disease models of depression affect treatment... - Efficacy of pregabalin in depressive symptoms associated with generalized anxiety disorder: a pooled analysis of 6 studiesDan J Stein
Department of Psychiatry and Mental Health, University of Cape Town, Cape Town, South Africa
Eur Neuropsychopharmacol 18:422-30. 2008..In conclusion, pregabalin, an alternative treatment option for GAD with a novel mechanism of action, also demonstrated efficacy in treating depressive symptoms typically encountered in GAD patients...